Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-anti-idiotype sdAb
- Development stage
- Preclinical
- Lead developer
- Vrije Universiteit Brussel
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-anti-idiotype sdAb is a preclinical radiopharmaceutical being investigated for the treatment of multiple myeloma, particularly for targeting minimal residual disease (MRD). It consists of a camelid-derived single-domain antibody (sdAb, or nanobody) that is radiolabeled with the beta-emitting isotope Lutetium-177 (177Lu). The sdAb is engineered to recognize the patient-specific idiotype of the membrane-bound paraprotein (M-protein) expressed on the surface of malignant plasma cells. This personalized approach allows for highly selective delivery of ionizing radiation to tumor cells while minimizing off-target effects. The research is primarily led by academic institutions in Belgium, including Vrije Universiteit Brussel (VUB) and UZ Brussel.
- Other names
- 177Lu-labeled anti-idiotypic nanobody177Lu-anti-idiotypic camelid single-domain antibody fragment
02
Targets
Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on 177Lu-anti-idiotype sdAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-anti-idiotype sdAb.